Cargando…
Alzheimer’s Transgenic Model Is Characterized by Very Early Brain Network Alterations and β-CTF Fragment Accumulation: Reversal by β-Secretase Inhibition
Alzheimer’s disease (AD) is defined by the presence of amyloid-β (Aβ) and tau protein aggregates. However, increasing data is suggesting that brain network alterations rather than protein deposition could account for the early pathogenesis of the disease. In the present study, we performed in vitro...
Autores principales: | Mondragón-Rodríguez, Siddhartha, Gu, Ning, Manseau, Frederic, Williams, Sylvain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952042/ https://www.ncbi.nlm.nih.gov/pubmed/29867356 http://dx.doi.org/10.3389/fncel.2018.00121 |
Ejemplares similares
-
The η-secretase-derived APP fragment ηCTF is localized in Golgi, endosomes and extracellular vesicles and contributes to Aβ production
por: Afram, Elissa, et al.
Publicado: (2023) -
Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?
por: Tang, Jordan, et al.
Publicado: (2011) -
β-Secretases, Alzheimer's Disease, and Down Syndrome
por: Webb, Robin L., et al.
Publicado: (2012) -
The Alzheimer's disease β-secretase enzyme, BACE1
por: Cole, Sarah L, et al.
Publicado: (2007) -
Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology
por: Lauritzen, Inger, et al.
Publicado: (2016)